Arcutis Biotherapeutics, Inc. (ARQT) vs Enliven Therapeutics, Inc. (ELVN)

Arcutis Biotherapeutics, Inc. and Enliven Therapeutics, Inc. are both Biotechnology companies. Arcutis Biotherapeutics, Inc. and Enliven Therapeutics, Inc. are of similar size ($3.4B and $3.3B). Enliven Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 122×. Arcutis Biotherapeutics, Inc. has the higher net margin (6.15% vs 0.00%) and the higher return on invested capital (23.6% vs 0.00%). Across the 14 metrics below, Arcutis Biotherapeutics, Inc. leads on 10 and Enliven Therapeutics, Inc. on 4.

Valuation

Metric ARQT ELVN Biotechnology median
P/E 122.36 n/m 7.88
P/S 7.57 n/m 11.47
P/B 15.93 3.31 2.52
Price to free cash flow 145.96 n/m 21.16
EV/EBITDA 95.16 n/m 0.74
EV/Sales 7.29 n/m 10.73
Earnings yield 0.82% (3.73%) (28.84%)
Free cash flow yield 0.69% (2.26%) (23.03%)

Profitability

Metric ARQT ELVN Biotechnology median
Gross margin 91.14% 0.00% 65.16%
Operating margin 7.38% 0.00% 0.00%
Net margin 6.15% 0.00% 0.00%
Free cash flow margin 8.42% 0.00% 0.00%
Return on equity 15.86% (15.31%) (57.72%)
Return on assets 6.78% (14.98%) (49.22%)
Return on invested capital 23.62% 0.00% 0.00%

Growth

Metric ARQT ELVN Biotechnology median
Revenue growth (TTM) 76.11% — 5.64%
EPS growth (last fiscal year) 88.79% 3.17% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARQT ELVN Biotechnology median
Debt to equity 0.49 0.00 0.00
Current ratio 2.92 64.07 4.73
Net debt to EBITDA 11.64 3.87 0.96

Dividend

Metric ARQT ELVN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARQT ELVN Biotechnology median
Market cap 3.39b 3.31b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack